曲安奈德玻璃体腔注射治疗视网膜黄斑分支静脉阻塞继发黄斑水肿

Intravitreal Triamcinolone Acetonide for the Treatment of Macular Edema Secondary to Macular Branch Retinal Vein Occlusion

目的评价玻璃体腔注射曲安奈德(intravitreal triamcinolone acetonide,IVTA)治疗黄斑分支静脉阻塞(macular branch retinal vein occlusion,MBRVO)继发黄斑水肿的疗效及安全性。方法经荧光素眼底血管造影(fluorescein fundus angiography,FFA)、光学相干断层扫描(optical coherence tomography,OCT)等检查确诊为 MBRVO 继发黄斑水肿并进行 IVTA 治疗的患者共51例(51眼),观察术前及术后最佳矫正视力、FFA 渗漏改变、OCT 显示的黄斑水肿变化及并发症。结果术后所有患者视力得到稳定或提高,相应的平均黄斑中心视网膜厚度降低,差异均有显著统计学意义(P<0.01)。治疗后6个月有44眼(86.3%)荧光渗漏消失或减轻,7眼(13.3%)不变或有所加重。8眼(16.4%)术后一过性眼压升高;3眼(5.9%)在术后6个月白内障明显进展;无感染性眼内炎及其他并发症发生。结论 IVTA是治疗 MBRVO 继发黄斑水肿的一种安全且有效的方法。(中国眼耳鼻喉科杂志,2007,7:311-312)

Purpose To evaluate the efficacy and security of intravitreal triamcinolone acetonide （IVTA） in the treatment of macular edema secondary to macular branch retinal vein occlusion （MBRVO）. Methods IVTA was performed in 51 eyes of 51 patients with macular edema secondary to MBRVO determined by fundus fluorescein angiography （FFA） and optic coherence tomography （OCT）. The best-corrected visual acuity （ BCVA ）, FFA, the macular thickness under OCT and the possible complications were recorded and analyzed. Results After IVTA treatment, the BCVA in all cases was either improved or kept stable with the average retinal thickness significantly decreased compared with that pretreatment （P 〈0.01 ）. Fluorescein leakage reduced significantly 6 months after treatment in 44 eyes（86.3% ）, with other 7 eyes （ 13.3% ） remained unchanged. Eight eyes （ 16.4% ） of all 51 eyes had high intraocular pressure （IOP） temporarily. Three eyes （5.9%） developed dense cataracts. There were no other complications. Conclusions IVTA might be a safe and effective method for the treatment of macular edema secondary to MBRVO. （ Chin J Ophthalmol and Otorhinolaryngol, 2007,7 ： 311-312 ）